| Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron T Šimůnek, M Štěrba, O Popelová, M Adamcová, R Hrdina, V Geršl Pharmacological reports 61 (1), 154-171, 2009 | 983 | 2009 |
| Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection M Štěrba, O Popelová, A Vávrová, E Jirkovský, P Kovaříková, V Geršl, ... Antioxidants & redox signaling 18 (8), 899-929, 2013 | 407 | 2013 |
| Anthracycline-induced cardiotoxicity R Hrdina, V Gersl, I Klimtová, T Simunek, J Machackova, M Adamcová ACTA MEDICA-HRADEC KRALOVE- 43 (3), 75-82, 2000 | 201 | 2000 |
| Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase H Kaiserová, T Šimůnek, WJF van Der Vijgh, A Bast, E Kvasničková Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1772 (9 …, 2007 | 175 | 2007 |
| Water-soluble non-aggregating zinc phthalocyanine and in vitro studies for photodynamic therapy S Makhseed, M Machacek, W Alfadly, A Tuhl, M Vinodh, T Simunek, ... Chemical Communications 49 (95), 11149-11151, 2013 | 172 | 2013 |
| SIH—a novel lipophilic iron chelator—protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death T Šimůnek, C Boer, RA Bouwman, R Vlasblom, AMG Versteilen, M Štěrba, ... Journal of molecular and cellular cardiology 39 (2), 345-354, 2005 | 116 | 2005 |
| Far-red-absorbing cationic phthalocyanine photosensitizers: synthesis and evaluation of the photodynamic anticancer activity and the mode of cell death induction M Machacek, A Cidlina, V Novakova, J Svec, E Rudolf, M Miletin, ... Journal of Medicinal Chemistry 58 (4), 1736-1749, 2015 | 113 | 2015 |
| The role of reactive oxygen and nitrogen species in cellular iron metabolism PŘE MladĚNka, TÁŠ ŠImŮNek, M HüBL, RÍR Hrdina Free radical research 40 (3), 263-272, 2006 | 106 | 2006 |
| Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity M Adamcova, M Šterba, T Šimunek, A Potacova, O Popelova, Y Mazurova, ... Expert opinion on drug safety 4 (3), 457-472, 2005 | 102 | 2005 |
| Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells A Vavrova, H Jansova, E Mackova, M Machacek, P Haskova, L Tichotova, ... PloS one 8 (10), e76676, 2013 | 88 | 2013 |
| Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury P Bendova, E Mackova, P Haskova, A Vavrova, E Jirkovsky, M Sterba, ... Chemical research in toxicology 23 (6), 1105-1114, 2010 | 87 | 2010 |
| Exploring the anti-cancer activity of novel thiosemicarbazones generated through the combination of retro-fragments: Dissection of critical structure-activity relationships M Serda, DS Kalinowski, N Rasko, E Potůčková, A Mrozek-Wilczkiewicz, ... PloS one 9 (10), e110291, 2014 | 83 | 2014 |
| Rabbit model for in vivo study of anthracycline‐induced heart failure and for the evaluation of protective agents T Šimůnek, I Klimtová, J Kaplanová, Y Mazurová, M Adamcová, M Štěrba, ... European journal of heart failure 6 (4), 377-387, 2004 | 82 | 2004 |
| Synthesis and Initial in Vitro Evaluations of Novel Antioxidant Aroylhydrazone Iron Chelators with Increased Stability against Plasma Hydrolysis K Hruskova, P Kovarikova, P Bendova, P Haskova, E Mackova, J Stariat, ... Chemical research in toxicology 24 (3), 290-302, 2011 | 79 | 2011 |
| In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity M Adamcová, T Šimůnek, H Kaiserová, O Popelová, M Štěrba, ... Toxicology 237 (1-3), 218-228, 2007 | 78 | 2007 |
| Proteomic insights into chronic anthracycline cardiotoxicity M Štěrba, O Popelová, J Lenčo, A Fučíková, E Brčáková, Y Mazurová, ... Journal of molecular and cellular cardiology 50 (5), 849-862, 2011 | 75 | 2011 |
| Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone T Šimůnek, M Štěrba, O Popelova, H Kaiserova, M Adamcova, M Hroch, ... British journal of pharmacology 155 (1), 138-148, 2008 | 72 | 2008 |
| Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways E Jirkovský, O Popelová, P Křiváková-Staňková, A Vávrová, M Hroch, ... Journal of Pharmacology and Experimental Therapeutics 343 (2), 468-478, 2012 | 66* | 2012 |
| Iron is not involved in oxidative stress‐mediated cytotoxicity of doxorubicin and bleomycin H Kaiserova, GJM Den Hartog, T Šimůnek, L Schröterová, E Kvasničková, ... British journal of pharmacology 149 (7), 920-930, 2006 | 66 | 2006 |
| Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death O Popelová, M Štěrba, P Hašková, T Šimůnek, M Hroch, I Gunčová, ... British journal of cancer 101 (5), 792-802, 2009 | 65 | 2009 |
